Polyphor flops a phase 3, jeopardizing its future as shares more than halved.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      SWITZERLAND
    • Abstract:
      Swiss biotech Polyphor has seen its key cancer asset balixafortide fail a late-stage trial, leaving its future in the balance. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of FierceBiotech is the property of Questex Media Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)